College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea.
Mol Cells. 2023 Apr 30;46(4):200-205. doi: 10.14348/molcells.2023.2164. Epub 2023 Feb 9.
DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a member of the phosphatidylinositol 3-kinase related kinase family is a well-known player in repairing DNA double strand break through non-homologous end joining pathway. This mechanism has allowed us to understand its critical role in T and B cell development through V(D)J recombination and class switch recombination, respectively. We have also learned that the defects in these mechanisms lead to severely combined immunodeficiency (SCID). Here we highlight some of the latest evidence where DNA-PKcs has been shown to localize not only in the nucleus but also in the cytoplasm, phosphorylating various proteins involved in cellular metabolism and cytokine production. While it is an exciting time to unveil novel functions of DNA-PKcs, one should carefully choose experimental models to study DNA-PKcs as the experimental evidence has been shown to differ between cells of defective DNA-PKcs and those of knockout. Moreover, while there are several DNA-PK inhibitors currently being evaluated in the clinical trials in attempt to increase the efficacy of radiotherapy or chemotherapy, multiple functions and subcellular localization of DNA-PKcs in various types of cells may further complicate the effects at the cellular and organismal level.
DNA 依赖性蛋白激酶催化亚基(DNA-PKcs)是磷脂酰肌醇 3-激酶相关激酶家族的成员,是通过非同源末端连接途径修复 DNA 双链断裂的知名参与者。这一机制使我们能够分别通过 V(D)J 重组和类别转换重组来理解其在 T 和 B 细胞发育中的关键作用。我们还了解到,这些机制的缺陷会导致严重联合免疫缺陷(SCID)。在这里,我们重点介绍了一些最新的证据,表明 DNA-PKcs 不仅定位于细胞核,还定位于细胞质,磷酸化参与细胞代谢和细胞因子产生的各种蛋白质。虽然揭示 DNA-PKcs 的新功能是令人兴奋的,但应该仔细选择实验模型来研究 DNA-PKcs,因为已经证明有缺陷的 DNA-PKcs 细胞和敲除细胞之间的实验证据存在差异。此外,虽然目前有几种 DNA-PK 抑制剂正在临床试验中评估,以试图提高放疗或化疗的疗效,但 DNA-PKcs 在各种类型细胞中的多种功能和亚细胞定位可能会进一步使细胞和机体水平的影响复杂化。